Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene Says QPCR, Reagent Sales Will Drive 7-Percent Growth in Q4 Revenue

NEW YORK (GenomeWeb News) — Stratagene today said it expects fourth-quarter revenue to be around $24.7 million, or 7 percent better than last year’s pro forma revenue of $23 million for the same period.
The uptick came largely from sales of the company’s QPCR products and reagents, which were up 7 percent, and from allergy diagnostics products, which were up 23 percent, Stratagene said.
However, Stratagene said it expects these increases to be offset by an expected drop in sales of its gene-discovery and cloning products.  
Stratagene did not say how much it expects these legacy sales to decrease, but EO Joseph Sorge said the company believes market growth for molecular and clinical diagnostics will “provide sizeable, long-term profitable revenue growth opportunities. …”

The company expects to release final fourth quarter and full year results in early March 2007. 

In the fourth quarter of 2005, Stratagene received a one-time payment of $34.1 million from Cambridge Antibody Technology for patent interests, which boosted total revenue to $57.1 million.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.